6533b85bfe1ef96bd12bb56a

RESEARCH PRODUCT

Immunotherapy: is a minor god yet in the pantheon of treatments for lung cancer?

Marta CastigliaEdgardo S. SantosEvelien SmitsGiuseppe BronteChristian RolfoFrancesco PassigliaGiovanni SortinoLuis E. RaezAnnelies JanssensPatrick PauwelsAntonio Russo

subject

OncologyPD-L1medicine.medical_specialtyLung NeoplasmsSettore MED/06 - Oncologia Medicamedicine.medical_treatmentRacotumomabIpilimumabCIMAvaxtecemotideCancer VaccinesracotumomabCancer immunotherapyCarcinoma Non-Small-Cell LungInternal medicinePD-1medicineHumansbelagenpumatucel-LPharmacology (medical)ipilimumabLung cancerGVAXnon-small cell lung cancerNeoplasm StagingClinical Trials as TopicMAGE-A3CIMAvax; GVAX; MAGE-A3; PD-1; PD-L1; TG4010; belagenpumatucel-L; immunotherapy; ipilimumab; non-small cell lung cancer; racotumomab; tecemotide; vaccinesbusiness.industryAntibodies MonoclonalCancerImmunotherapyvaccinesmedicine.diseaseGVAXOncologyImmunologyTecemotideTG4010Human medicineimmunotherapybusinessmedicine.drug

description

Abstract: Immunotherapy has been studied for many years in lung cancer without significant results, making the majority of oncologists quite skeptical about its possible application for non-small cell lung cancer treatment. However, the recent knowledge about immune escape and subsequent cancer immunoediting has yielded the development of new strategies of cancer immunotherapy, heralding a new era of lung cancer treatment. Cancer vaccines, including both whole-cell and peptide vaccines have been tested both in early and advanced stages of non-small cell lung cancer. New immunomodulatory agents, including anti-CTLA4, anti-PD1/PDL1 monoclonal antibodies, have been investigated as monotherapy in metastatic lung cancer. To date, these treatments have shown impressive results of efficacy and tolerability in early clinical trials, leading to testing in several large, randomized Phase III trials. As these results will be confirmed, these drugs will be available in the near future, offering new exciting therapeutic options for lung cancer treatment.

yearjournalcountryeditionlanguage
2014-08-22
10.1586/14737140.2014.952287http://hdl.handle.net/10447/112723